The expanding role of blood and tissue establishments in the development of advanced therapy medicinal products

被引:1
|
作者
Horan, Aisling [1 ]
Warreth, Shada [2 ,3 ]
Hervig, Tor [1 ,4 ]
Waters, Allison [1 ,5 ]
机构
[1] Natl Blood Ctr, Irish Blood Transfus Serv, Jamess St, Dublin D08 NH5R, Ireland
[2] Technol Univ Dublin, Sch Chem & Pharmaceut Sci, Dublin, Ireland
[3] Natl Inst Bioproc Res & Training NIBRT, Belfield, Dublin, Ireland
[4] Trinity Coll Dublin, Sch Med, Dublin, Ireland
[5] Univ Coll Dublin, UCD Sch Publ Hlth Physiotherapy & Social Sci, Dublin, Ireland
关键词
advanced therapeutic medicinal products; ATMP; blood establishment; cellular therapy; GMP; Good Manufacturing Practice; Introduction;
D O I
10.1016/j.jcyt.2024.02.012
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background aims: The relationship between blood establishments and advanced cellular therapies is evident in several European countries, with some involved in research and development and/or in manufacturing. The aim of the present study was to understand the advanced therapy medicinal product (ATMP) infrastructural, regulatory and logistic requirements needed for the Irish Blood Transfusion Service to support advanced therapeutics in Ireland. Methods: An online survey consisting of 13 questions was distributed in a targeted manner to the identi fied ATMP stakeholders in Ireland, namely those working in industry, health care, regulatory agencies or education. Subject matter experts in the field were approached and interviewed to gain further insight into the relationship between blood and tissue establishments (BTEs) and ATMPs, to explore the advantages these institutions have in development and to highlight potential challenges for implementation. Results: In total, 84.9% of survey respondents stated that BTEs have a role in the development of advanced therapeutics. Key BTE services identi fied as applicable to the ATMP sector from both surveys and interviews include the provision of starting materials for research and manufacturing, donor management, use of existing quality and traceability frameworks, product logistic strategies and Good Manufacturing Practice. Challenges for BTE expansion into the sector currently include high costs associated with ATMPs, lack of expertise in these therapies, limited therapeutic populations and no national ATMP strategic plan for Ireland. Conclusions: Blood establishments have services and expertise that can be extended into the advanced therapy sector. The existing knowledge and skill base of BTEs in Ireland should be leveraged to accelerate the development of ATMP strategies for industry and healthcare. (c) 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
引用
收藏
页码:524 / 530
页数:7
相关论文
共 50 条
  • [41] Risk management considerations and advanced therapy medicinal products
    Ruppert-Seipp, G.
    Muller, S.
    Berg, P.
    Funk, M. B.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A194 - A194
  • [42] Advanced Therapy Medicinal Products: an introduction to risk management
    Silva Junior, Joao Batista
    Mendes Takao, Marilia Rodrigues
    Parca, Renata Miranda
    VIGILANCIA SANITARIA EM DEBATE-SOCIEDADE CIENCIA & TECNOLOGIA, 2018, 6 (01): : 23 - 31
  • [43] European Regulatory Tools for Advanced Therapy Medicinal Products
    Flory, Egbert
    Reinhardt, Jens
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2013, 40 (06) : 409 - 412
  • [44] ROLE OF BASIC RESEARCH IN DEVELOPMENT OF MEDICINAL PRODUCTS
    BRUNINGS, KJ
    RESEARCH MANAGEMENT, 1979, 22 (04): : 19 - 23
  • [45] Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe
    Farkas, Andreas M.
    Mariz, Segundo
    Stoyanova-Beninska, Violeta
    Celis, Patrick
    Vamvakas, Spiros
    Larsson, Kristina
    Sepodes, Bruno
    FRONTIERS IN MEDICINE, 2017, 4
  • [46] Development of a UK national network of GMP facilities for the manufacture of advanced therapy medicinal products (ATMPs)
    Hollyman, D.
    Austin, E.
    Smith, K.
    Hadley, A.
    Bateman, I.
    Gillan, H.
    Lloyd-Evans, P.
    Watt, S. M.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S511 - S511
  • [47] Challenges in development, market authorisation and commercialisation of advanced therapy medicinal products in Europe: A cohort study
    ten Ham, ten Renske M. T.
    Hoekman, Jarno
    Hovels, Anke M.
    Broekmans, Andre W.
    Leufkens, Hubert G. M.
    Klungel, Olaf H.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 428 - 428
  • [48] Advanced Therapy Medicinal Products for Eye Diseases: Goals and Challenges
    Diebold, Yolanda
    Garcia-Posadas, Laura
    PHARMACEUTICS, 2021, 13 (11)
  • [49] The New Regulation of Advanced Therapy Medicinal Products in the European Union
    Ruiz, Sol
    MOLECULAR THERAPY, 2009, 17 : S395 - S395
  • [50] Payer and Implementation Challenges with Advanced Therapy Medicinal Products (ATMPs)
    John Spoors
    Alec Miners
    John Cairns
    Danny Palnoch
    Ash Summerfield
    Joanne McEntee
    Sheena Vithlani
    BioDrugs, 2021, 35 : 1 - 5